Revolution Medicines (RVMD) CDO details initial option and RSU stake
Rhea-AI Filing Summary
Revolution Medicines, Inc. Chief Development Officer Alan B. Sandler filed an initial beneficial ownership report. He directly holds 53,000 shares of Common Stock, which include 53,000 Restricted Stock Units. He also holds stock options over 167,300 shares at an exercise price of $58.84 per share expiring on October 31, 2035, and options over 11,700 shares at $102.02 per share expiring on February 28, 2036. These options vest monthly over four years starting from vesting commencement dates on November 1, 2025 and March 1, 2026, subject to his continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
3 transactions reported
Mixed
3 txns
Insider
Sandler Alan B.
Role
Chief Development Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 179,000 shares (Direct);
Common Stock — 53,000 shares (Direct)
Footnotes (3)
- F1. Includes 53,000 Restricted Stock Units.
- F2. Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from November 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
- F3. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did RVMD Chief Development Officer Alan Sandler report on his Form 3?
Alan Sandler reported his initial beneficial ownership in Revolution Medicines. He holds 53,000 Common Stock shares including Restricted Stock Units and stock options over additional shares that vest over time, subject to his continued service with the company.
What stock options does Alan Sandler have in Revolution Medicines (RVMD)?
Alan Sandler holds options over 167,300 RVMD shares at an exercise price of $58.84 expiring October 31, 2035. He also holds options over 11,700 shares at $102.02 expiring February 28, 2036, providing potential future ownership if exercised.
How do Alan Sandler’s RVMD stock options vest over time?
One option grant vests 25% on November 1, 2026, then monthly so it is fully vested by the fourth anniversary of November 1, 2025. The other grant vests monthly from March 1, 2026, also completing on its fourth anniversary, contingent on continued service.
What is the significance of Alan Sandler’s Form 3 for RVMD investors?
The Form 3 shows Alan Sandler’s initial equity stake as Chief Development Officer. It details his Restricted Stock Units and option grants, illustrating long-term, service-based incentives that link a key executive’s potential rewards to Revolution Medicines’ share performance.